This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Beer, T. M. Articles by Myrthue, A. Search for Related Content PubMed PubMed Citation Articles by Beer, T. M. Articles by Myrthue, A. Related Collections Therapeutics and Targets Therapeutics and Targets: Drug Mechanisms and Resistance

Minireview

Calcitriol in cancer treatment: From the lab to the clinic

Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR

Requests for Reprints: Tomasz M. Beer, Department of Medicine, Oregon Health and Science University, Mail Code CR-145, 3181 SW Sam Jackson Park Road, Portland, OR 97239. Phone: (503) 494-0365; Fax: (503) 494-6197. E-mail: beert{at}ohsu.edu

1,25-Dihydroxyvitamin D (calcitriol), the most active metabolite of vitamin D, has significant antineoplastic activity in preclinical models. Several mechanisms of activity have been proposed. These include inhibition of proliferation associated with cell cycle arrest and, in some models, differentiation, reduction in invasiveness and angiogenesis, and induction of apoptosis. Proposed mechanisms differ between tumor models and experimental conditions, and no unifying hypothesis about the mechanism of antineoplastic activity has emerged. Synergistic and/or additive effects with cytotoxic chemotherapy, radiation, and other cancer drugs have been reported. Significantly supraphysiological concentrations of calcitriol are required for antineoplastic effects. Such concentrations are not achievable in patients when calcitriol is dosed daily due to predictable hypercalcemia and hypercalcuria; however, phase I trials have demonstrated that intermittent dosing allows substantial dose escalation and has produced potentially therapeutic peak calcitriol concentrations. Recently, a phase II study reported encouraging levels of activity for the combination of high-dose calcitriol and docetaxel administered on a weekly schedule in patients with androgen-independent prostate cancer. This regimen is now under study in a placebo-controlled randomized trial in androgen-independent prostate cancer and in phase II studies in several other tumor types. Further work is needed to elucidate the molecular mechanisms of antineoplastic activity and optimal clinical applications of calcitriol in cancer.

Note: T.M. Beer receives research support from Aventis Pharmaceuticals and Novacea, is a member of the Aventis Speakers' Bureau, a consultant to Novacea, and a co-inventor in a patent licensed to Novacea.

Received 10/15/03; revised 1/12/03; accepted 1/16/04.